Kazia Therapeutics Limited (KZIA)

$4.18

-0.01 (-0.24%)
Rating:
Recommendation:
Neutral
Symbol KZIA
Price $4.18
Beta 2.767
Volume Avg. 0.27M
Market Cap 60.067M
Shares () -
52 Week Range 3.81-12.28
1y Target Est -
DCF Unlevered KZIA DCF ->
DCF Levered KZIA LDCF ->
ROE -61.76% Strong Sell
ROA -28.88% Sell
Operating Margin -
Debt / Equity 75.22% Buy
P/E -
P/B 2.98 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest KZIA news


Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (
Healthcare
Biotechnology
NASDAQ Capital Market

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.